Close association of UGT1A9 IVS1+399C>T with UGT1A1*28,*6, or *60 haplotype and its apparent influence on 7-Ethyl-10- hydroxycamptothecin (SN-38) glucuronidation in Japanese

Drug Metabolism and Disposition

Volumn 37, Issue 2, 2009, Pages 272-276

  Saito, Yoshiro ^a   Sai, Kimie ^a   Maekawa, Keiko ^a   Kaniwa, Nahoko ^a   Shirao, Kuniaki ^b,h   Hamaguchi, Tetsuya ^b   Yamamoto, Noboru ^b   Kunitoh, Hideo ^b   Ohe, Yuichiro ^b   Yamada, Yasuhide ^b   Tamura, Tomohide ^b   Yoshida, Teruhiko ^c   Minami, Hironobu ^d,i   Ohtsu, Atsushi ^e   Matsumura, Yasuhiro ^f   Saijo, Nagahiro ^g   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Division of Oncology/Hematology   (Japan)

^e Division of Gastrointestinal Oncology/Digestive Endoscopy   (Japan)

^f Research Center for Innovative Oncology   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h OITA UNIVERSITY   (Japan)

ⁱ KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; CISPLATIN; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG GLUCURONIDATION; DRUG INACTIVATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; LINKAGE (GENETICS); MUTATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 59749087186     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024208     Document Type: Article

References (16)

1. Beutler E, Gelbart T, and Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
2. Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, and Wrighton SA (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltrans-ferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727-739.
3. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
4. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, and Guillemette C (2006) The novel UGT1A9 intronic I399 polymorphism seems as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 34:1220-1228.
5. Inoue K, Miura M, Satoh S, Kagaya H, Saito M, Habuchi T, and Suzuki T (2007) Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 29:299-304.
6. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, Di Rienzo A, and Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
7. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, and Sawada J (2003) Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 31:108-113.
8. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, et al. (2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497-504.
9. Ramírez J, Liu W, Mirkov S, Desai AA, Chen P, Das S, Innocenti F, and Ratain MJ (2007) Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos 35:2149-2153.
10. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, et al. (2006) Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 6:63-75.
11. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, et al. (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515.
12. Saito Y, Maekawa K, Ozawa S, and Sawada J (2007) Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenomics 5:49-78.
13. Sandanaraj E, Jada SR, Shu X, Lim R, Lee SC, Zhou Q, Zhou S, Goh BC, and Chowbay B (2008) Influence of UGT1A9 intronic I399>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J 8:174-185.
14. Smith NF, Figg WD, and Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20:163-175.
15. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, and Miwa M (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292:492-497.
16. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.